Innate Pharma S.A. (IPHA) PT Raised to $16 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts IPHA Hot Sheet
Price: $1.46 -2.67%
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz raised the price target on Innate Pharma S.A. (NASDAQ: IPHA) to $16.00 (from $14.00) while maintaining a Buy rating.
You May Also Be Interested In
- Citi Downgrades Volvo AB (VOLVB:SS) (VLVLY) to Neutral
- Dixon Technologies India Ltd (DIXON:IN) PT Lowered to INR15,300 at HSBC
- Citi raises General Dynamics price target to $400, keeps Neutral
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
